10-K: Fortrea Holdings Inc. Reports Fiscal Year 2024 Results; Outlines Strategic Priorities for Growth

Fortrea Holdings Inc. releases its 10-K filing, detailing its financial performance for the fiscal year ended December 31, 2024, and outlining its strategic initiatives as a leading global contract research organization.

Summary

• Fortrea Holdings Inc., a global contract research organization, has filed its Form 10-K for the fiscal year ended December 31, 2024.
• The company reported revenues of $2.6964 billion for 2024, a 5.1% decrease compared to $2.8425 billion in 2023.
• This decline is attributed to a 5.2% decrease in organic revenue, influenced by lower pass-through costs and reduced service revenues due to fewer new business wins prior to the spin-off from Labcorp.
• Direct costs decreased by 4.0% to $2.1622 billion, representing 80.2% of revenues, compared to 79.2% in the previous year.
• Selling, general, and administrative expenses increased by 25.1% to $560.7 million, driven by higher professional fees and costs associated with operating as a standalone company.
• The company recorded restructuring charges of $50.1 million in 2024 related to streamlining operations and eliminating redundant positions.
• Interest expense increased to $123.8 million due to higher overall debt balance and write-off of debt issuance costs.
• As of December 31, 2024, Fortrea's backlog was $7.7 billion.
• The company sold its Enabling Services segment during the second quarter of 2024, resulting in a loss on disposal of $19.6 million.
• Fortrea is focusing on scientific and therapeutic expertise, site support, global scale, technology investment, and partnerships to drive future growth.
• The company has an aggregate principal amount of indebtedness of approximately $1.142 billion as of December 31, 2024.
• Fortrea has a $450 million senior secured revolving credit facility, from which $826.5 million of receivables were sold for net proceeds of $297.9 million during the year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights strategic strengths and future growth plans, it also acknowledges a decline in revenue and increased expenses. The overall tone is cautiously optimistic.

Positives

• Fortrea is strategically positioned to serve the pharmaceutical, biotechnology, and medical device industries.
• The company has a large and diversified customer base.
• Fortrea has global and stable customer relationships.
• The company has access to actionable clinical data and insights.
• Fortrea has expertise across therapeutic areas.
• The company is pursuing ideal scale to support the research requirements of its customers.
• Fortrea is aligning with innovators through selective investment in technology, data and application of AI for speed and simplification.
• The company is building on strengths in clinical pharmacology.
• Fortrea is creating an inclusive culture for careers with meaning as a competitive advantage.

Negatives

• Fortrea's 2024 revenue decreased by 5.1% compared to 2023.
• The company experienced increased selling, general, and administrative expenses.
• Fortrea recorded restructuring charges of $50.1 million.
• The company incurred a loss on the disposal of its Enabling Services segment.
• Fortrea's business is subject to a number of risks inherent to our industry, including our customers ability to access sufficient funding to run clinical trials, our ability to generate net new business awards or our new business awards being delayed, terminated, reduced in scope, or failing to go to contract, and our ability to contract with suitable investigators and recruit and enroll patients for clinical trials, among others.

Risks

• The company's business, financial condition, results of operations, or cash flows may be materially adversely affected if it does not generate a large number of net new business awards, or if net new business awards are delayed, terminated, reduced in scope, or fail to go to contract.
• If the company is unable to contract with suitable investigators and recruit and enroll patients for clinical trials, its business might suffer.
• The company's international operations could subject it to additional risks and expenses that could adversely impact its business or results of operations.
• The company's customer or therapeutic area concentrations may have a material adverse effect on its business, financial condition, results of operations or cash flows.
• The company's customers may experience insufficient funding to complete their clinical trials.
• The company's backlog might not be indicative of its future revenues, and it might not realize all of the anticipated future revenue reflected in its backlog.
• The company operates in a highly competitive industry.
• An inability to attract and retain experienced and qualified personnel, including key management personnel and increased personnel costs, could adversely affect its business.
• The company depends on third parties to provide services critical to its business.
• The company's business is dependent upon access to data and an inability to access the necessary data from its data partners on commercially reasonable terms or at all could adversely affect its business.
• If the company is unable to achieve and maintain effective internal controls, its business, financial condition, results of operations, and cash flows could be materially adversely affected.
• The company's effective income tax rate may fluctuate, which could adversely affect its operations.

Future Outlook

Fortrea's growth strategy builds on its strong foundation and aligns with its customers' priorities, including leading with scientific and therapeutic expertise, expanding in existing and novel therapeutic areas, supporting sites to solve patient recruitment and trial start problems, pursuing ideal scale to support research requirements, aligning with innovators through technology, and becoming the partner of choice for pharmaceutical, biotechnology, and medical device companies.

Management Comments

• Fortreas employees are motivated by our purpose of delivering solutions that bring life-changing medicines to patients faster, and we are committed to making Fortrea an engaging place where talented professionals can grow and advance their careers.

Industry Context

The CRO market is expected to grow more slowly in the short term, and return to a higher growth rate in the longer term. The biopharmaceutical industry is highly competitive, and we regularly provide services to customers that are developing competing drugs.

Comparison to Industry Standards

• Competitors in the CRO industry range from hundreds of smaller CROs to a limited number of large CROs with global capabilities.
• Examples include the expansion of decentralized trial (DCT) services, global logistics, and management of highly complex biologics and cell and gene therapy trials.
• Fortrea has strategic relationships with a number of top technology vendors in the industry, including Advarra, Cognizant, Medidata and Veeva among others.

Legal Proceedings

• The outcomes of such proceedings are inherently unpredictable and subject to significant uncertainties.
• Based on currently available information, we do not expect that any pending or threatened claim or legal action, either individually or in the aggregate, will have a material adverse effect on the business, our financial condition, results of operations, and/or our cash flows.
• As part of working with this customer, the Company made concessions and provided discounts and other consideration to the customer in the amount of approximately $12.5 million as part of a multi-party solution to facilitate the trials, of which $3.8 million and $8.7 million was recorded as a reduction of revenue for the years ended December 31, 2024 and 2023, respectively.
• For the year ended December 31, 2024, the Company recorded legal expenses of $2.2 million related to the settlement of legal matters initiated prior to the spin.

Stakeholder Impact

• The company's performance and strategic decisions impact shareholders, employees, customers, suppliers, and creditors.
• The company is committed to increasing the representation of patient populations within clinical trials, and we developed a holistic strategy focused on partnering with customers, sites, investigators, and communities to address this commitment.

Next Steps

• Fortrea will continue to strategically invest in markets to meet the needs of its customers and the demands of the global clinical trial landscape.
• The company plans to continue to invest in its capabilities, its ability to generate insights through data and analytics, reduce cost, and increase the speed and efficiency of clinical trial execution to enhance the quality of our offerings for our customers.

Key Dates

Keywords

contract research organization, clinical trials, biopharmaceutical, clinical development, CRO, Fortrea, revenue, backlog, financial results, pharmaceutical, biotechnology, medical device